@Article{信息:doi 10.2196 / / jmir。2640，作者=“van Gaalen, Johanna L和Beerthuizen, Thijs和van der Meer, Victor和van Reisen, Patricia和Redelijkheid, Geertje W和Snoeck-Stroband, Jiska B和Sont, Jacob K”，标题=“基于互联网的成人哮喘自我管理支持的长期结果:随机对照试验”，期刊=“J Med Internet Res”，年=“2013”，月=“Sep”，日=“12”，卷=“15”，数=“9”，页=“e188”，关键词=“哮喘;生活质量;自我管理;长期的;电子健康;互联网;背景:长期哮喘管理达不到国际指南设定的目标。互联网被认为是一种有吸引力的媒介，以支持哮喘的指导自我管理。最近，在一项随访1年的多中心、实用的随机对照平行试验中，患者被分配了基于互联网的自我管理(IBSM)支持(互联网组[IG])或单独的常规护理(UC)。 IBSM support was automatically terminated after 12 months of follow-up. In this study, IBSM support has been demonstrated to improve asthma-related quality of life, asthma control, lung function, and the number of symptom-free days as compared to UC. IBSM support was based on known key components for effective self-management and included weekly asthma control monitoring and treatment advice, online and group education, and communication (both online and offline) with a respiratory nurse. Objective: The objective of the study was to assess the long-term effects of providing patients 1 year of IBSM support as compared to UC alone. Methods: Two hundred adults with physician-diagnosed asthma (3 or more months of inhaled corticosteroids prescribed in the past year) from 37 general practices and 1 academic outpatient department who previously participated were invited by letter for additional follow-up at 1.5 years after finishing the study. The Asthma Control Questionnaire (ACQ) and the Asthma Quality of Life Questionnaire (AQLQ) were completed by 107 participants (60 UC participants and 47 IG participants). A minimal clinical important difference in both questionnaires is 0.5 on a 7-point scale. Results: At 30 months after baseline, a sustained and significant difference in terms of asthma-related quality of life of 0.29 (95{\%} CI 0.01-0.57) and asthma control of -0.33 (95{\%} CI -0.61 to -0.05) was found in favor of the IBSM group. No such differences were found for inhaled corticosteroid dosage or for lung function, measured as forced expiratory volume in 1 second. Conclusions: Improvements in asthma-related quality of life and asthma control were sustained in patients who received IBSM support for 1 year, even up to 1.5 years after terminating support. Future research should be focused on implementation of IBSM on a wider scale within routine asthma care. Trial Registration: International Standard Randomized Controlled Trial Number (ISRCTN): 79864465; http://www.controlled-trials.com/ISRCTN79864465 (Archived by WebCite at http://www.webcitation.org/6J4VHhPk4). ", issn="14388871", doi="10.2196/jmir.2640", url="//www.mybigtv.com/2013/9/e188/", url="https://doi.org/10.2196/jmir.2640", url="http://www.ncbi.nlm.nih.gov/pubmed/24028826" }